Y Intercept Hong Kong Ltd Buys Shares of 21,728 Maze Therapeutics, Inc. $MAZE

Y Intercept Hong Kong Ltd purchased a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 21,728 shares of the company’s stock, valued at approximately $649,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its position in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Maze Therapeutics during the 4th quarter valued at approximately $39,000. Ameritas Investment Partners Inc. lifted its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics during the 4th quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the period.

Maze Therapeutics Trading Down 4.5%

Shares of Maze Therapeutics stock opened at $29.18 on Tuesday. Maze Therapeutics, Inc. has a 1 year low of $12.81 and a 1 year high of $53.65. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The business has a 50 day moving average price of $26.68 and a 200 day moving average price of $35.22. The company has a market capitalization of $1.62 billion, a P/E ratio of -11.53 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. Sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on MAZE shares. HC Wainwright raised their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price target on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $66.00.

Insider Activity

In related news, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. The trade was a 59.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 14,609 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10. Following the completion of the transaction, the chief marketing officer owned 14,609 shares in the company, valued at approximately $436,809.10. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 141,470 shares of company stock worth $3,887,939 over the last three months. 5.30% of the stock is currently owned by corporate insiders.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.